HLA發(fā)表關(guān)于細(xì)胞表面抗原的免疫遺傳學(xué)研究的完整原創(chuàng)文章、簡(jiǎn)要通訊、評(píng)論和偶爾的評(píng)論;免疫系統(tǒng)的個(gè)體發(fā)育和系統(tǒng)發(fā)育;細(xì)胞相互作用的免疫遺傳學(xué);細(xì)胞表面分子及其天然配體的功能方面，如細(xì)胞因子、粘附分子和活化抗原;組織抗原在體內(nèi)外免疫反應(yīng)中的作用，包括實(shí)驗(yàn)和臨床移植;以及正常組織抗原和腫瘤相關(guān)抗原之間的關(guān)系。該雜志強(qiáng)調(diào)免疫反應(yīng)的遺傳控制、疾病易感性和遺傳學(xué)、同種抗原的生物化學(xué)和分子生物學(xué)以及白細(xì)胞分化。手稿被邀請(qǐng)表達(dá)在淋巴細(xì)胞、髓細(xì)胞、血小板和非系限制性抗原上的分子。人類(lèi)和實(shí)驗(yàn)動(dòng)物組織相容性抗原的免疫遺傳學(xué)及其在正常細(xì)胞和惡性細(xì)胞中的組織分布、調(diào)控和表達(dá)，以及作為疾病標(biāo)志物的抗原的研究具有重要意義。目標(biāo)和范圍HLA發(fā)表完整的原創(chuàng)文章，簡(jiǎn)短的交流，評(píng)論和評(píng)論涵蓋了免疫遺傳控制的所有方面。范圍包括功能、生化和免疫系統(tǒng)的分子遺傳研究,包括細(xì)胞表面受體及其配體,包括細(xì)胞因子、趨化因子、粘附和主要分子,細(xì)胞等抗原受體,NKR, CD1、pamp, Igs、吉珥,基因和產(chǎn)品的主要組織相容性復(fù)合體包括經(jīng)典和非經(jīng)典的HLA分子。論文應(yīng)描述體外或動(dòng)物模型的原始研究，或反映實(shí)體器官或造血干細(xì)胞移植、自身免疫、感染免疫、過(guò)敏、腫瘤免疫、疫苗科學(xué)、妊娠和疾病易感性免疫遺傳學(xué)的臨床研究。該雜志的重點(diǎn)是通過(guò)以下途徑了解免疫的遺傳控制:·免疫基因組學(xué)，包括基因組織、系統(tǒng)發(fā)育、進(jìn)化、調(diào)控、多態(tài)性，特別是影響表達(dá)和功能的多態(tài)性、群體遺傳學(xué)、基因標(biāo)記(例如。微衛(wèi)星和單核苷酸多態(tài)性)和打字應(yīng)用或方法?！っ庖咧匾肿拥牡鞍谆蚩乖磉_(dá)和生物化學(xué)，包括翻譯后調(diào)控、細(xì)胞表面表達(dá)、亞型、血清學(xué)、組織表達(dá)、白細(xì)胞分化抗原、細(xì)胞活化和分化標(biāo)志物、髓細(xì)胞和淋巴細(xì)胞表面抗原、血小板抗原、胸腺標(biāo)志物和非譜系細(xì)胞表面分子所定義的細(xì)胞譜系關(guān)系?！た刂泼庖邞?yīng)答的分子結(jié)構(gòu)與功能，包括細(xì)胞表面分子及其配體、粘附分子、細(xì)胞因子、趨化因子、抗原受體如TcR、免疫球蛋白、NKR、toll樣受體、HLA、KIR、CD1、MICA/B、PAMPs、補(bǔ)體等免疫效應(yīng)分子。誘騙受體、細(xì)胞因子類(lèi)似物和凋亡抑制劑或其他細(xì)胞功能等病原體對(duì)免疫反應(yīng)的調(diào)節(jié)。·免疫遺傳學(xué)工具，包括新基因、序列、單克隆抗體、多態(tài)性數(shù)據(jù)庫(kù)，特別是HLA等位基因、人群數(shù)據(jù)、健康和疾病中的HLA肽庫(kù)、小組織相容性抗原的定義、等位基因變異、基因圖譜和生物信息學(xué)?；仡櫸恼?，評(píng)論，簡(jiǎn)短的交流和人們?cè)诿庖哌z傳學(xué)。請(qǐng)就該雜志所涵蓋領(lǐng)域的最新發(fā)展發(fā)表評(píng)論文章(最多12頁(yè))。歡迎以一頁(yè)摘要的形式向評(píng)論編輯提交建議。評(píng)論簡(jiǎn)要探討當(dāng)前的重要話(huà)題。鼓勵(lì)簡(jiǎn)短的交流報(bào)告基因序列，MHC肽基序和單克隆抗體和疾病易感性的研究?！睹庖哌z傳學(xué)》雜志的人(最多2頁(yè))強(qiáng)調(diào)了一個(gè)或多個(gè)人對(duì)涉及該個(gè)人的特定近期事件的科學(xué)貢獻(xiàn)。會(huì)議或工作坊報(bào)告。會(huì)議前與總編聯(lián)系，確定是否接受。向GenBank或歐洲核苷酸檔案(ENA)提交序列數(shù)據(jù)。原稿中描述的核苷酸或氨基酸序列數(shù)據(jù)也必須在提交前提交給GenBank或ENA。不接受含有DNA或蛋白質(zhì)序列而沒(méi)有加入號(hào)的手稿。新等位基因序列應(yīng)符合國(guó)際命名委員會(huì)的要求，如新的HLA等位基因需要對(duì)完整的基因進(jìn)行測(cè)序，以便對(duì)其進(jìn)行正確的定義，并應(yīng)已由世衛(wèi)組織HLA系統(tǒng)因子命名委員會(huì)命名。

HLA publishes full-length original articles, brief communications, commentaries and occasional reviews on research in: immunogenetics of cell surface antigens; ontogeny and phylogeny of the immune system; immunogenetics of cell interactions; functional aspects of cell surface molecules and their natural ligands, such as cytokines, adhesion molecules and activation antigens; role of tissue antigens in immune reactions in vitro and in vivo, including experimental and clinical transplantation; and relationships between normal tissue antigens and tumor-associated antigens.The journal emphasizes genetic control of immune response, disease susceptibility and genetics, biochemistry and molecular biology of alloantigens and leukocyte differentiation. Manuscripts are invited on molecules expressed on lymphoid cells, myeloid cells, platelets and non-lineage-restricted antigens. The immunogenetics of histocompatibility antigens in humans and experimental animals and their tissue distribution, regulation and expression in normal and malignant cells and antigens as markers for disease are of major interest.Aims and ScopeHLA publishes full-length original articles, brief communications, commentaries and reviews covering all aspects of genetic control of immunity. The scope includes functional, biochemical, and genetic studies on molecules of the immune system, including cell surface receptors and their ligands, and encompassing cytokines, and chemokines, adhesion and co-stimulating molecules, antigen receptors such as TcR, NKR, CD1, PAMPs, Igs, KIR, and genes and products of the major histocompatibility complex including classical and non-classical HLA molecules. Papers should describe original research in vitro, or in animal models, or be clinical studies reflecting genetics of immunity in solid organ or haematopoietic stem cell transplantation, autoimmunity, infectious immunity, allergy, tumour immunity, vaccine science, pregnancy and disease susceptibility. The journal emphasis is on understanding genetic control of immunity through:· Immunogenomics including gene organisation, phylogeny, evolution, regulation, polymorphism particularly where it affects expression and function, population genetics, gene markers (eg.microsatellites and SNPs) and typing applications or methodology.· Protein or antigen expression and biochemistryof immunologically important molecules including post-translational regulation, cell surface expression, isoforms, serology, tissue expression, cell lineage relationships particularly defined by leucocyte differentiation antigens, cell activation and differentiation markers, myeloid and lymphoid cell surface antigens, platelet antigens, thymic markers and non-lineage cell surface molecules.· Structure and function of molecules that control immune responsesincluding cell surface molecules and their ligands, adhesion molecules, cytokines, chemokines, antigen receptors such as TcR, immunoglobulins, NKR, Toll-like receptors, HLA, KIR, CD1, MICA/B, PAMPs, Complement and other immune effector molecules. Modulation of immune responses by pathogens such as decoy receptors, cytokine analogs and inhibitors of apoptosis or other cellular functions.· Immunogenetic tools including new genes, sequences, mAbs, polymorphism databases particularly HLA alleles, population data, HLA-peptide repertoires in health and disease, definition of minor histocompatibility antigens, allelic variants, gene maps and bioinformatics.Review articles, Commentaries, Brief communications and People in Immunogenetics. Review articles (maximum 12 printed pages) on recent developments in areas covered by the journal are invited. Suggestions are welcomed in the form of a one-page synopsis submitted to the Reviews Editor. Commentaries briefly explore important current topics.Brief communications are encouraged for reporting gene sequences, MHC peptide motifs and studies of monoclonal antibodies and disease susceptibility. People in Immunogenetics (maximum 2 printed pages) highlight the scientific contributions of one or more people in relation to a specific recent event involving the person(s).Reports of meeting or workshops. Contact the Editor-in-Chief before the meeting to determine acceptability.Submission of sequence data to GenBank or the European Nucleotide Archive (ENA). Original nucleotide or amino acid sequence data described in manuscripts must also be submitted to GenBank or ENA before submission. Manuscripts containing DNA or protein sequences without an accession number are not accepted. Sequences of new alleles should meet the requirements of international nomenclature committees e.g. New HLA alleles require sequencing of complete genes for their proper definition and should have been named by the WHO Nomenclature Committee for Factors of the HLA System.